The Department of Veterans Affairs announced the launch of PIVOT, Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression, a multi-site randomized controlled trial comparing two psilocybin dosage levels in veterans with treatment-resistant major depressive disorder, with or without concurrent PTSD. It is the VA’s own sponsored efficacy trial, run through its Office of Research and Development, not a study VA participates in as a site for someone else’s protocol. That distinction matters, and it lands alongside a second, closely related data point this desk has independently verified: an open-label pilot trial in veterans with severe, treatment-resistant PTSD, run through Ohio State University’s Center for Psychedelic Drug Research and Education and published just days before PIVOT’s launch, reporting no serious adverse events and a 75 percent remission rate at one month. Read together, these describe an institution moving from cautious research participation toward sponsoring its own efficacy trials, backed by an early result striking enough that its own lead author called it exactly that.
What PIVOT actually is
PIVOT is registered on ClinicalTrials.gov as a multi-site randomized controlled trial, sponsored directly by the VA Office of Research and Development, comparing outcomes between two psilocybin dosage levels in veterans diagnosed with treatment-resistant major depressive disorder. The trial assesses depression severity before and after treatment, tolerability of side effects, and patient-reported outcomes. VA Secretary Doug Collins framed the launch plainly: “Far too many Veterans are living with mental health conditions that don’t respond to available treatments… VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform.” The trial is a long-horizon commitment, with primary completion not estimated until December 2030 and full completion in mid-2031, a genuinely multi-year efficacy program rather than a short pilot.
The result it launches alongside
Separately, and not run by the VA itself, researchers at Ohio State’s Center for Psychedelic Drug Research and Education published an open-label pilot trial in Communications Medicine examining psilocybin-assisted therapy in twelve veterans with severe, treatment-resistant PTSD. Participants received two psilocybin doses, 15 milligrams followed by 25 milligrams two to three weeks later, alongside roughly eight hours of therapy before and after each session. The safety profile was clean: no serious adverse events, and no increase in suicidal thinking or behavior, a meaningful finding in a population selected specifically for severity and treatment resistance. The efficacy signal was, in the study’s own framing, unusually strong: 75 percent of participants were in remission one month after the study concluded, no longer meeting PTSD diagnostic criteria at all. Lead author Stacey Armstrong described the results as striking specifically because of the population studied, patients who had already failed conventional treatment and typically face elevated risk of dropout, long-term disability, and suicide.
Why the pairing matters more than either study alone
PIVOT targets depression, not PTSD, and uses a different sponsor and design than the Ohio State pilot. They are not the same study, and this piece is not claiming PIVOT’s outcome based on a different trial’s result. What the pairing does show is an institutional pattern: the VA is now involved in 20 active clinical trials focused on psychedelic therapies for mental health conditions, spanning multiple sponsors, multiple indications, and now including a trial the VA itself directly sponsors and controls. A federal health system moving from supporting psychedelic research broadly to running its own efficacy trial is a real posture shift, and it is happening at the same moment closely adjacent research in the same patient population is producing results specific enough to describe as striking rather than merely promising.
The caveat VA states plainly, and this desk should too
VA’s own announcement is explicit that this remains research, not a change in clinical policy: “Clinical use of these therapies outside of research will only be considered by VA once FDA approval is granted. VA strongly discourages self-medicating or attempting to replace other mental health treatment options with psychedelics or any other unprescribed substance.” That caveat is worth taking as seriously as the trial launch itself. Nothing about PIVOT or the Ohio State result changes what’s available to a veteran today, and VA is making that distinction explicit in its own messaging rather than leaving it implied.
Why this belongs next to the desk’s existing coverage
This desk has tracked the VA’s institutional posture on psychedelics closely this year, the HHS-VA memorandum of understanding signed in July, built explicitly around preparing workforce and data infrastructure for a future approved product, and the broader federal coordination that MOU represents. PIVOT is a concrete, funded instance of exactly the kind of clinical-trial participation that MOU was designed to expand, and the Ohio State pilot’s remission data is precisely the sort of veteran-specific evidence that MOU explicitly says should inform future FDA regulatory and coverage decisions. Together, these are not three separate stories. They are the same institutional shift showing up in a policy document, a funded trial, and a published result, within a matter of weeks of each other.
The caveats
The Ohio State pilot is open-label, uncontrolled, and enrolled twelve participants, real limitations on how far its remission figure should be generalized, and its own authors describe it as a safety and feasibility study rather than a definitive efficacy trial. PIVOT itself is randomized and controlled, a meaningfully more rigorous design, but as of this writing it is only just launching, with results not expected for years. Neither trial should be read as evidence that psilocybin is close to becoming an approved or accessible treatment for veterans specifically, and VA’s own statement makes that explicit.
The frame
A federal health system this size sponsoring its own randomized controlled psilocybin trial, rather than only supporting research led by others, is a genuine institutional marker, and it arrives days after a smaller, veteran-specific study reported results strong enough to draw the word striking from its own lead investigator. Neither fact alone would be more than an incremental update to a story this desk has followed all year. Together, they describe an institution whose posture toward this drug class has moved further, and faster, than a single announcement suggests, while VA’s own caution that none of this changes what’s actually available to a veteran today remains the most important sentence in its own press release.